Affimed GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 51

Market Cap: -

Website: http://www.affimed.com

Clinical Trials

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Phase 2

Recruiting

Conditions: Relapsed or Refractory Hodgkin Lymphoma
Peripheral T Cell Lymphoma

Interventions: Drug: AFM13
Drug: AB-101
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2

First Posted Date: 2023-06-01

Last Posted Date: 2024-11-13

Lead Sponsor: Affimed GmbH

Target Recruit Count: 154

Registration Number: NCT05883449

Locations: 🇺🇸
UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 12 locations

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: AFM28

First Posted Date: 2023-04-18

Last Posted Date: 2024-07-03

Lead Sponsor: Affimed GmbH

Target Recruit Count: 24

Registration Number: NCT05817058

Locations: 🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇫🇷
Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
🇩🇰
Rigshospitalet, Copenhagen, Denmark

and more 3 locations

Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: AFM24
Drug: Atezolizumab 840 MG in 14 ML Injection

First Posted Date: 2021-11-05

Last Posted Date: 2024-10-02

Lead Sponsor: Affimed GmbH

Target Recruit Count: 148

Registration Number: NCT05109442

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇵🇱
Independent Public Teaching Hospital #4 in Lublin, Department of Clinical Oncology and Chemotherapy, Lublin, Poland

and more 13 locations

Study to Assess AFM24 in Advanced Solid Cancers

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: 14 mg AFM24
Drug: 40 mg AFM24
Drug: 160 mg AFM24
Drug: 480 mg AFM24
Drug: 320 mg AFM24
Drug: 80 mg AFM24
Drug: 720 mg AFM24

First Posted Date: 2020-02-06

Last Posted Date: 2024-08-29

Lead Sponsor: Affimed GmbH

Target Recruit Count: 85

Registration Number: NCT04259450

Locations: 🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇩🇪
University Duisburg-Essen, University Hospital Essen, Essen, Germany
🇩🇪
Nordwest Hospital GmbH, Frankfurt am Main, Hessen, Germany

and more 10 locations

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Phase 2

Completed

Conditions: Peripheral T Cell Lymphoma
Transformed Mycosis Fungoides

Interventions: Drug: AFM13

First Posted Date: 2019-09-24

Last Posted Date: 2024-11-05

Lead Sponsor: Affimed GmbH

Target Recruit Count: 108

Registration Number: NCT04101331

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of California Los Angeles (UCLA) Health, Los Angeles, California, United States
🇺🇸
Ochsner Clinic Foundation/Precision Cancer Therapies Program, New Orleans, Louisiana, United States

and more 66 locations

Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL

Phase 1

Terminated

Conditions: Leukemia, B-Cell

Interventions: Drug: AFM11

First Posted Date: 2016-07-29

Last Posted Date: 2019-06-19

Lead Sponsor: Affimed GmbH

Target Recruit Count: 17

Registration Number: NCT02848911

Locations: 🇵🇱
Independent Public Healthcare Municipal Hospital, Chorzow, Poland
🇷🇺
Almazov NW Federal Medical Research Center, St. Petersburg, Russian Federation
🇷🇺
First Pavlov State Medical University, St. Petersburg, Russian Federation

and more 8 locations

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin Lymphoma

Interventions: Biological: AFM13
Biological: Pembrolizumab

First Posted Date: 2016-01-28

Last Posted Date: 2019-05-16

Lead Sponsor: Affimed GmbH

Target Recruit Count: 30

Registration Number: NCT02665650

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Coral Gables, Florida, United States
🇺🇸
Washington University Medical Center, Saint Louis, Missouri, United States
🇪🇸
Fundacion Privada Instituto de Investigacion Oncologica de Vall Hebron, Barcelona, Spain

and more 13 locations

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Phase 1

Terminated

Conditions: Relapsed B-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: AFM11

First Posted Date: 2014-04-08

Last Posted Date: 2019-06-18

Lead Sponsor: Affimed GmbH

Target Recruit Count: 16

Registration Number: NCT02106091

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇵🇱
SP ZOZ University Hospital Krakow, Krakow, Poland
🇵🇱
MTZ Clinical Research, Warsaw, Poland

and more 4 locations

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: AFM 13

First Posted Date: 2010-10-15

Last Posted Date: 2013-06-26

Lead Sponsor: Affimed GmbH

Target Recruit Count: 28

Registration Number: NCT01221571

Locations: 🇩🇪
University Hosptial Cologne, Koln, Köln, Germany
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇩🇪
University Hospital Würzburg, Würzburg, Germany

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy